Perfromance Wealth Partners’s Sarepta Therapeutics SRPT Stock Holding History

Perfromance Wealth Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,726	Closed	-$210K	–	186
2024 Q4	$210K	Sell	1,726 -1,200	-41%	-$147K	0.01%	173
2024 Q3	$365K	Sell	2,926 -1,074	-27%	-$148K	0.01%	125
2024 Q2	$632K	Buy	4,000 +1,500	+60%	+$193K	0.02%	74
2024 Q1	$324K	Buy	+2,500	New	+$306K	0.01%	122
2023 Q4	–	Sell	-2,700	Closed	-$327K	–	178
2023 Q3	$327K	Buy	2,700 +500	+23%	+$56.5K	0.02%	131
2023 Q2	$246K	Hold	2,200	–	–	0.01%	159
2023 Q1	$303K	Buy	2,200 +600	+38%	+$77.8K	0.02%	141
2022 Q4	$207K	Buy	+1,600	New	+$185K	0.01%	157

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Perfromance Wealth Partners's SRPT Position: Q1 2025 in Review

Perfromance Wealth Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 1,726 shares — an estimated $210K sold.

Perfromance Wealth Partners first reported a position in SRPT in Q4 2022 and held it in 8 quarters. The position peaked at $632K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Perfromance Wealth Partners reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Perfromance Wealth Partners sold 1,726 Sarepta Therapeutics shares in Q1 2025, an estimated $210K.
Perfromance Wealth Partners first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 8 quarters.
Perfromance Wealth Partners's Sarepta Therapeutics position peaked at $632K in Q2 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Perfromance Wealth Partners's 13F filing for Q1 2025, filed 22 Apr 2025.